264 related articles for article (PubMed ID: 32497081)
1. S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity.
Dowarha D; Chou RH; Yu C
PLoS One; 2020; 15(6):e0234152. PubMed ID: 32497081
[TBL] [Abstract][Full Text] [Related]
2. Functional interaction between S100A1 and MDM2 may modulate p53 signaling in normal and malignant endometrial cells.
Nakagawa M; Higuchi S; Hashimura M; Oguri Y; Matsumoto T; Yokoi A; Ishibashi Y; Ito T; Saegusa M
BMC Cancer; 2022 Feb; 22(1):184. PubMed ID: 35177036
[TBL] [Abstract][Full Text] [Related]
3. S100 proteins interact with the N-terminal domain of MDM2.
van Dieck J; Lum JK; Teufel DP; Fersht AR
FEBS Lett; 2010 Aug; 584(15):3269-74. PubMed ID: 20591429
[TBL] [Abstract][Full Text] [Related]
4. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
6. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
7. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
8. The C-terminal SAM domain of p73 binds to the N terminus of MDM2.
Neira JL; Díaz-García C; Prieto M; Coutinho A
Biochim Biophys Acta Gen Subj; 2019 Apr; 1863(4):760-770. PubMed ID: 30735716
[TBL] [Abstract][Full Text] [Related]
9. Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction.
Ciemny MP; Debinski A; Paczkowska M; Kolinski A; Kurcinski M; Kmiecik S
Sci Rep; 2016 Dec; 6():37532. PubMed ID: 27905468
[TBL] [Abstract][Full Text] [Related]
10. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
[TBL] [Abstract][Full Text] [Related]
11. Phosphomimetic mutation of the N-terminal lid of MDM2 enhances the polyubiquitination of p53 through stimulation of E2-ubiquitin thioester hydrolysis.
Fraser JA; Worrall EG; Lin Y; Landre V; Pettersson S; Blackburn E; Walkinshaw M; Muller P; Vojtesek B; Ball K; Hupp TR
J Mol Biol; 2015 Apr; 427(8):1728-47. PubMed ID: 25543083
[TBL] [Abstract][Full Text] [Related]
12. Structural details on mdm2-p53 interaction.
Chi SW; Lee SH; Kim DH; Ahn MJ; Kim JS; Woo JY; Torizawa T; Kainosho M; Han KH
J Biol Chem; 2005 Nov; 280(46):38795-802. PubMed ID: 16159876
[TBL] [Abstract][Full Text] [Related]
13. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
[TBL] [Abstract][Full Text] [Related]
14. S100A4 inhibits cell proliferation by interfering with the S100A1-RAGE V domain.
Khan MI; Yuan T; Chou RH; Yu C
PLoS One; 2019; 14(2):e0212299. PubMed ID: 30779808
[TBL] [Abstract][Full Text] [Related]
15. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
16. Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.
Hu M; Gu L; Li M; Jeffrey PD; Gu W; Shi Y
PLoS Biol; 2006 Feb; 4(2):e27. PubMed ID: 16402859
[TBL] [Abstract][Full Text] [Related]
17. Kinetic and thermodynamic effects of phosphorylation on p53 binding to MDM2.
Yadahalli S; Neira JL; Johnson CM; Tan YS; Rowling PJE; Chattopadhyay A; Verma CS; Itzhaki LS
Sci Rep; 2019 Jan; 9(1):693. PubMed ID: 30679555
[TBL] [Abstract][Full Text] [Related]
18. The Mechanism of p53 Rescue by SUSP4.
Kim DH; Lee C; Lee SH; Kim KT; Han JJ; Cha EJ; Lim JE; Cho YJ; Hong SH; Han KH
Angew Chem Int Ed Engl; 2017 Jan; 56(5):1278-1282. PubMed ID: 28000315
[TBL] [Abstract][Full Text] [Related]
19. Recognition Dynamics of p53 and MDM2: Implications for Peptide Design.
ElSawy KM; Lane DP; Verma CS; Caves LS
J Phys Chem B; 2016 Jan; 120(2):320-8. PubMed ID: 26701330
[TBL] [Abstract][Full Text] [Related]
20. CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery.
Dey DK; Sharma C; Vadlamudi Y; Kang SC
Life Sci; 2023 Apr; 318():121476. PubMed ID: 36758667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
